Biodegradation and bioaccumulation of fenitrothion in rat liver

Shalini Roy1, Sharmila Roy, Reena Kumar

  • 1Department of Bioscience and Biotechnology, I.I.T. Roorkee-247667, India. shalubas2000@yahoo.com

Insights

Fenitrothion biodegradation in rat liver involves sequential conversion to amino and phosphate metabolites. Chronic exposure showed excretion, not bioaccumulation, of fenitrothion and its breakdown products.

Area of Science:

  • Environmental toxicology
  • Biochemistry
  • Pharmacokinetics

Background:

  • Fenitrothion is an organophosphate pesticide.
  • Understanding its metabolic fate in mammals is crucial for risk assessment.

Purpose of the Study:

  • To investigate the biodegradation pathways of fenitrothion in rat liver.
  • To characterize fenitrothion metabolites under acute and chronic exposure.
  • To assess the bioaccumulation potential of fenitrothion.

Main Methods:

  • Acute and chronic administration of fenitrothion to rats.
  • High-performance liquid chromatography (HPLC) for separation and quantification.
  • Infrared (IR) spectroscopy for metabolite identification.

Main Results:

  • Fenitrothion was sequentially converted to three major metabolites within 24 hours in acute treatment.
  • Metabolite identification revealed nitro reduction, P-O-aryl bond hydrolysis, and oxidative desulfurylation.
  • Chronic treatment showed no metabolite bioaccumulation, but continuous reduction in fenitrothion concentration.

Conclusions:

  • Fenitrothion undergoes dose-dependent biodegradation in rat liver.
  • Excretion in urine and feces prevents significant bioaccumulation.
  • Metabolic pathways involve nitro reduction and P-O-aryl bond cleavage.

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...